Evra transdermal patch (ethinylestradiol norelgestromin): Reviews and patient testimonials


/static/themes-v3/default/images/default/opinion/traitement/intro.jpg?1720004028

Back Back to the list of medications

Medication indications

Evra transdermal patch

Female contraception

EVRA is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years.

The decision to prescribe EVRA should take into consideration the individual woman's current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with EVRA compares with other CHCs (see sections 4.3 and 4.4).


Route of administration: opinion.traitement.transdermal
Molecule: ethinylestradiol, norelgestromin

Patients' opinions on Evra transdermal patch

In brief

General satisfaction level: 10.00/10 Learn more

Treatment's effectiveness: 10.00/10 Learn more

Ease of use: 10.00/10 Learn more

Adherence to prescription: 10.00/10 Learn more

Detected side effects: 2.00/10 Learn more

Improvement in the quality of life: 10.00/10 Learn more

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Not at all satisfied
10 = Extremely satisfied

1 = Never
10 = Always

1 = Not at all important
10 = Extremely important

1 = Not at all satisfied
10 = Extremely satisfied

Tips and advice of the community

Join Carenity and be the first to give your opinion on this medication.